Alcohol use disorder in community management of chronic liver diseases

Lorenzo Leggio, Jessica L. Mellinger – 16 April 2022 – Rising rates of alcohol use disorder (AUD) combined with increases in alcohol‐related liver disease (ALD) and other liver disease have resulted in the need to develop alcohol management strategies at all levels of patient care. For those with pre‐existing liver disease, whether ALD or others, attention to alcohol use treatment and abstinence becomes critical to avoiding worsening liver‐related consequences.

Standardizing the histological assessment of late posttransplantation biopsies from pediatric liver allograft recipients

Stefan G. Hübscher, Sandy Feng, Annette S. H. Gouw, Hironori Haga, Hyo Jeong Kang, Deirdre A. Kelly, Mina Komuta, Andrew Lesniak, Benjamin A. Popp, Henkjan J. Verkade, Eunsil Yu, Anthony J. Demetris – 15 April 2022 – Excellent short‐term survival after pediatric liver transplantation (LT) has shifted attention toward the optimization of long‐term outcomes. Despite considerable progress in imaging and other noninvasive modalities, liver biopsies continue to be required to monitor allograft health and to titrate immunosuppression.

Proteomics‐based identification of the role of osteosarcoma amplified‐9 in hepatocellular carcinoma recurrence

Xuyong Wei, Mengfan Yang, Binhua Pan, Xiaobing Zhang, Hanchao Lin, Wangyao Li, Wenzhi Shu, Kun Wang, Abdul Rehman Khan, Xuanyu Zhang, Beini Cen, Xiao Xu – 15 April 2022 – Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies; its recurrence is associated with high mortality and poor recurrence‐free survival and is affected by multisystem and multilevel pathological changes.

Elevated fractional donor‐derived cell‐free DNA during subclinical graft injury after liver transplantation

Anna K. Baumann, Julia Beck, Theresa Kirchner, Björn Hartleben, Ekkehard Schütz, Michael Oellerich, Heiner Wedemeyer, Elmar Jaeckel, Richard Taubert – 15 April 2022 – Personalized immunosuppression (IS) promises to improve the balance of necessary control of alloreactivity and dose‐dependent adverse effects of long‐term IS such as kidney insufficiency, infections, and malignancies.

Subscribe to